This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Conan Kornetsky, PhD

Arch Gen Psychiatry. 1976;33(12):1425-1428.

Abstract
• Among the evidence supporting the dopamine hypothesis of schizophrenia is the finding that both amphetamine and methylphenidate hydrochloride, potent releasers of dopamine, can cause exacerbation of symptoms in the acute schizophrenic patient. The present report describes three experiments in which the effects of amphetamine in chronic schizophrenic patients were studied. In one of the experiments, orally administered, daily doses of 20 mg of dextroamphetamine sulfate given at 8 PM had little or no effect on the sleep duration of the subjects. In the other two experiments, doses up to 40 mg given orally also had little or no effect on the performance of the subjects on a variety of behavioral tests. There was no evidence of an exacerbation of the disease process in any of the subjects. The most consistent amphetamine effect was a dose-related increase in blood pressure. These results indicate that the chronic schizophrenic patient may be hyporesponsive to amphetamine and suggest that if the dopamine hypothesis is correct, then it must be modified to take into account these findings in the chronic patient.

Author Affiliations
From the Boston University School of Medicine, Boston.

Footnotes
Accepted for publication Sept 20, 1976.

Reprint requests to Boston University School of Medicine, 80 E Concord St, Boston, MA 02118 (Dr Kornetsky).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sources of Diagnostic Uncertainty for Chronically Psychotic Cocaine Abusers
Shaner et al.
Psychiatr. Serv. 1998;49:684-690.
ABSTRACT | FULL TEXT  

m-Chlorophenylpiperazine Effects in Neuroleptic-Free Schizophrenic Patients: Evidence Implicating Serotonergic Systems in the Positive Symptoms of Schizophrenia
Krystal et al.
Arch Gen Psychiatry 1993;50:624-635.
ABSTRACT  

The Use of Psychostimulants in General Psychiatry: A Reconsideration
Chiarello and Cole
Arch Gen Psychiatry 1987;44:286-295.
ABSTRACT  

Antipsychotic Effects of Pimozide in Schizophrenia: Treatment Response Prediction With Acute Dextroamphetamine Response
van Kammen et al.
Arch Gen Psychiatry 1982;39:261-266.
ABSTRACT  

Long-term Pimozide Pretreatment Differentially Affects Behavioral Responses to Dextroamphetamine in Schizophrenia: Further Exploration of the Dopamine Hypothesis of Schizophrenia
van Kammen et al.
Arch Gen Psychiatry 1982;39:275-281.
ABSTRACT  

Lack of Behavioral Supersensitivity to d-Amphetamine After Pimozide Withdrawal: A Trial With Schizophrenic Patients
van Kammen et al.
Arch Gen Psychiatry 1980;37:287-290.
ABSTRACT  

A Neuroendocrine Study of Supersensitivity in Tardive Dyskinesia
Tamminga et al.
Arch Gen Psychiatry 1977;34:1199-1203.
ABSTRACT